Dr. Huhn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 W Harrison St
Chicago, IL 60612Phone+1 312-572-4575Fax+1 312-572-4502
Education & Training
Rush University Medical CenterFellowship, Infectious Disease, 2004 - 2005
Duke University HospitalResidency, Internal Medicine, 1996 - 1999
Tulane University School of MedicineClass of 1996
Certifications & Licensure
IL State Medical License 2003 - 2026
NC State Medical License 1997 - 2005- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Study on Immunopathogenesis in HIV and Hepatitis C Coinfection Start of enrollment: 2011 Jul 01
- DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects Start of enrollment: 2012 Jan 01
- Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy Start of enrollment: 2013 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 30 citationsExcess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?Brian R. Wood, Gregory Huhn
Open Forum Infectious Diseases. 2021-11-17 - 17 citationsA randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic...Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L. Gottlieb, Peter Chen
Clinical Infectious Diseases. 2021-10-28 - 22 citationsA Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.Ramesh Nathan, Imad Shawa, Inmaculada de la Torre, Jennifer M. Pustizzi, Natalie Haustrup
Infectious Diseases and Therapy. 2021-08-10
Journal Articles
- Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19Barry Heller, Gregory Huhn, Valentina Stosor, Imad Shawa, JAMA
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Robert L Gottlieb, Joseph Boscia, Gregory Huhn, Valentina Stosor, Imad Shawa, The New England Journal of Medicine
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Robert L Gottlieb, Joseph Boscia, Gregory Huhn, Valentina Stosor, Imad Shawa, The New England Journal of Medicine
- Join now to see all
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Join now to see all
Press Mentions
As New COVID Variants Emerge at a Faster Pace, Here's What You Need to KnowOctober 29th, 2022- New COVID Variants Emerging ‘More Quickly' Now. Here's What That SignalsOctober 28th, 2022
- Illinois Seeing ‘Uptick' in COVID Cases, Health Department SaysOctober 28th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
